The design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial - Summary - MDSpire

The design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial

  • By

  • Matthew C Mauck

  • Kelly S Barth

  • Kevin M Bell

  • Amber K Brooks

  • Andrea L Chadwick

  • Cameron A Gunn

  • Robert W Hurley

  • Anastasia Ivanova

  • Sara R Piva

  • Michael J Schneider

  • Jeannie F Bailey

  • Sarah Bagaason

  • Anna Batorsky

  • Jeffrey J Borckardt

  • Anton E Bowden

  • Timothy S Carey

  • Joel Castellanos

  • Lucy Chen

  • Brooke Chidgey

  • Diane Dalton

  • Jonathan S Dufour

  • Aaron J Fields

  • Julie M Fritz

  • Rachel West Goolsby

  • Carol M Greco

  • Richard E Harris

  • Steven Harte

  • Afton L Hassett

  • Anna Hoffmeyer

  • Sara Jones Berkeley

  • Chelsea Kaplan

  • Kelley M Kidwell

  • Gregory G Knapik

  • Michael R Kosorok

  • Gregorij Kurillo

  • Remy Lobo

  • Jeffrey C Lotz

  • Sean Mackey

  • Prasath Mageswaran

  • Sharmila Majumdar

  • Jianren Mao

  • William S Marras

  • Micah McCumber

  • Samuel A McLean

  • Wolf Mehling

  • Ulrike H Mitchell

  • Vitaly J Napadow

  • Conor O'Neill

  • Kushang V Patel

  • Scott Peltier

  • Matthew Psioda

  • Bryce Rowland

  • Sean D Rundell

  • Andrew Schrepf

  • John Sperger

  • Nam Vo

  • Mark S Wallace

  • Ajay D Wasan

  • Tristan E Weaver

  • Kenneth A Weber

  • David A Williams

  • Leslie Wilson

  • Fadel Zeidan

  • Beibo Zhao

  • Kevin J Anstrom

  • Daniel J Clauw

  • Gwendolyn A Sowa

  • April 9, 2025

  • 0 min

Share

Objective:

To identify optimal treatment responses for chronic low back pain (cLBP) based on individual patient features, including biomarkers and phenotypic measures, emphasizing the need for personalized treatment strategies.

Key Findings:
  • cLBP affects 13.1% of individuals aged 20-69 in the U.S. and is a leading cause of disability, underscoring the urgency for effective treatment strategies.
  • Current treatments yield modest improvements, highlighting the critical need for personalized treatment approaches that consider individual patient characteristics.
  • The BEST trial aims to identify biomarkers and phenotypic characteristics that predict treatment responses, potentially transforming the management of cLBP.
Interpretation:

The trial seeks to enhance treatment efficacy for cLBP by employing a precision medicine approach, which could lead to significantly improved patient outcomes through tailored interventions based on individual characteristics.

Limitations:
  • The study's findings may be limited by the specific population enrolled, which may not represent the broader cLBP population, affecting the applicability of results.
  • Potential biases in self-reported treatment responses could affect outcome assessments, necessitating careful interpretation of the findings.
Conclusion:

The BEST trial represents a significant step towards personalized treatment for cLBP, aiming to improve clinical decision-making through the identification of effective biomarkers and phenotypic measures.

Original Source(s)

The design and rationale of the Biomarkers for Evaluating Spine Treatments trial: a sequential multiple assignment randomized trial

  • by Matthew C Mauck, Kelly S Barth, Kevin M Bell, Amber K Brooks, Andrea L Chadwick, Cameron A Gunn, Robert W Hurley, Anastasia Ivanova, Sara R Piva, Michael J Schneider, Jeannie F Bailey, Sarah Bagaason, Anna Batorsky, Jeffrey J Borckardt, Anton E Bowden, Timothy S Carey, Joel Castellanos, Lucy Chen, Brooke Chidgey, Diane Dalton, Jonathan S Dufour, Aaron J Fields, Julie M Fritz, Rachel West Goolsby, Carol M Greco, Richard E Harris, Steven Harte, Afton L Hassett, Anna Hoffmeyer, Sara Jones Berkeley, Chelsea Kaplan, Kelley M Kidwell, Gregory G Knapik, Michael R Kosorok, Gregorij Kurillo, Remy Lobo, Jeffrey C Lotz, Sean Mackey, Prasath Mageswaran, Sharmila Majumdar, Jianren Mao, William S Marras, Micah McCumber, Samuel A McLean, Wolf Mehling, Ulrike H Mitchell, Vitaly J Napadow, Conor O'Neill, Kushang V Patel, Scott Peltier, Matthew Psioda, Bryce Rowland, Sean D Rundell, Andrew Schrepf, John Sperger, Nam Vo, Mark S Wallace, Ajay D Wasan, Tristan E Weaver, Kenneth A Weber, David A Williams, Leslie Wilson, Fadel Zeidan, Beibo Zhao, Kevin J Anstrom, Daniel J Clauw, Gwendolyn A Sowa

  • April 9, 2025

Related Content

Identification of Distinct Biopsychosocial Phenotypes in Young Adults with Chronic Postsurgical Pain through Resting-State Cortical Activity, Biomarkers, and Functional Performance

Childhood Experiences of Parental Distress and Their Impact on Pain-Related Thoughts Throughout Life: An Exploratory Study

Side Effects: Salt, Steroids, and Second Brains

So get this: sodium may track with memory decline (in men), steroids might not be “immunosuppressive” in the ICU, and second pregnancies reshape the brain differently than first. Same theme: biology is less binary than we teach it.